Independent information services
Guides, comparisons, and research summaries for people trying to understand the limited evidence, unresolved questions, and significant safety concerns around ibogaine and Parkinson’s disease.
Wide Anchor 84 helps readers distinguish early hypotheses from established care without presenting experimental ibogaine as a clinical recommendation.
What we provide
The starting point is the core guide to ibogaine Parkinson’s clinical trials, built for people with Parkinson’s, care partners, and families who want clear distinctions between possibility, evidence, and risk.
Parkinson’s disease is a progressive neurological condition, and its broad clinical context is summarized by the National Institute of Neurological Disorders and Stroke. That context matters when experimental claims are compared with established care.
We organize early findings, open questions, and study limitations in plain language. For a changing stream of claims and discussion, readers can compare the framing found at ibogaine news coverage with the evidence context presented here.
Our trial guide focuses on the questions worth asking about eligibility, endpoints, monitoring, and uncertainty. The resource’s approach and boundaries explain why no experimental result should be treated as established Parkinson’s care.
We place Parkinson’s-focused claims alongside adjacent ibogaine discussions, including information concerning ibogaine and opioid addiction, without treating one use case as evidence for another.
Terms such as clinical trial, endpoint, adverse event, and informed consent can shape how a claim is understood. A useful starting definition of clinical trial design helps clarify why careful methods matter.
Evidence is not transferable simply because two conditions involve the same compound.
Context before conclusions
Interest in ibogaine sometimes travels across conditions and settings. We flag those comparisons rather than allowing them to stand in for Parkinson’s-specific evidence, including discussion of ibogaine for brain injury.
Location-based treatment language can also obscure differences in legal status, oversight, and medical screening. Readers encountering claims about ibogaine treatment in Colorado or ibogaine treatment options in Mexico can use this resource to keep experimental Parkinson’s questions separate from destination-based marketing.
Ibogaine itself has a documented history and pharmacological interest, but that background does not establish a Parkinson’s treatment role; the overview of ibogaine’s history and chemistry is useful only as general context.
How to use the material
These are information services, not medical services. They are designed to help a reader slow down, identify what is known, and recognize what still requires qualified medical guidance.
Reader-centered perspective
These review-style reflections describe the questions this resource is designed to support; they are not clinical endorsements or accounts of treatment outcomes.
“I need the difference between a compelling story and evidence to be visible, not buried.”
“Safety should be part of the first conversation, not an afterthought.”
“A careful guide should make uncertainty easier to see and discuss.”
Common questions
Wide Anchor 84 is an independent resource for understanding experimental ibogaine research in relation to Parkinson’s disease.
No. Wide Anchor 84 is not a clinic, medical provider, or licensed treatment center. The material is educational and does not replace individualized medical advice.
No. Summaries organize limited evidence and uncertainty; they do not establish effectiveness. Registered studies can be searched through the official ClinicalTrials.gov database, where study status and details should be checked directly.
Because an experimental claim cannot be understood apart from its methods, monitoring, risks, and limitations. Those questions are especially important for people comparing anecdotal accounts with formal research.
Use the information to prepare careful questions for qualified healthcare professionals familiar with an individual’s health situation, medications, and Parkinson’s care. No page here is a substitute for that conversation.
Independent resource
Use these guides to evaluate claims carefully, understand why trial design matters, and keep established care distinct from experimental ibogaine discussions.